Critical Care

ATHOS-3: Angiotensin II for the Treatment of Vasodilatory Shock

ATHOS-3 Trial Visual summary on Angiotensin II

ATHOS-3 Trial Summary:

A total of 321 patients with vasodilatory shock on high dose catecholamines were randomized to angiotensin II or placebo. Within 3 hours, ~70% of in the angiotensin II group showed significant improvement in their mean arterial pressure as compared with 23.4% patients in placebo group (p<0.0001). Despite improvement in pressures, there was no signficant change in 28-days mortality among the two groups. The authors concluded that angiotensin II has the potential to effectively increase BP in patients who did not respond to high doses of conventional vasopressors.

ATHOS-3 Trial 2017, Angiotensin II for the Treatment of Vasodilatory Shock, NEJM